MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Trial Profile

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Phase of Trial: Phase I/II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Sapanisertib (Primary)
  • Indications Merkel cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2015 Status changed from not yet recruiting to recruiting, according to record.
    • 06 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top